192 related articles for article (PubMed ID: 34251745)
1. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S
Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745
[TBL] [Abstract][Full Text] [Related]
2. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
[TBL] [Abstract][Full Text] [Related]
3. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
4. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
6. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH
Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610
[TBL] [Abstract][Full Text] [Related]
8. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
11. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.
Xu M; Doyle MM; Banan B; Vachharajani N; Wang X; Saad N; Fowler K; Brunt EM; Lin Y; Chapman WC
J Am Coll Surg; 2017 Jul; 225(1):28-40. PubMed ID: 28400300
[TBL] [Abstract][Full Text] [Related]
13. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
14. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
[TBL] [Abstract][Full Text] [Related]
15. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
19. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy.
Finkenstedt A; Vikoler A; Portenkirchner M; Mülleder K; Maglione M; Margreiter C; Moser P; Vogel W; Bale R; Freund M; Luger A; Tilg H; Petersen J; Schneeberger S; Graziadei I; Zoller H; Glodny B
Liver Int; 2016 May; 36(5):688-95. PubMed ID: 26386273
[TBL] [Abstract][Full Text] [Related]
20. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
